Burlingame, March 01, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global PEGylated proteins market is estimated to be valued at US$ 14,424.3 million in 2022 and is expected to exhibit a CAGR of 4.7% during the forecast period (2022-2030).
Key Trends and Analysis of the Global PEGylated Proteins Market:
Key companies in the market are focusing on product approval for PEGylated Proteins which is expected to drive the market growth over the forecast period. For instance, in June 2020, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, announced that the U.S. Food and Drug Administration (FDA) had approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). It is a PEGylated leukocyte growth-stimulating factor indicated to reduce the incidence of febrile neutropenia in patients receiving anticancer drugs.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5354
PEGylated Proteins Market Report Coverage
| Report Coverage | Details | |||
| Base Year: | 2021 | Market Size in 2022: | US$ 14,424.3 Mn | |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 | |
| Forecast Period 2022 to 2030 CAGR: | 4.7% | 2030 Value Projection: | US$ 20,813.0 Mn | |
| Geographies covered: |
| |||
| Segments covered: |
| |||
| Companies covered: | Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd. | |||
| Growth Drivers: |
| |||
| Restraints & Challenges: |
| |||
Key Market Takeaways:
The global PEGylated proteins market is expected to exhibit a CAGR of 4.7% during the forecast period due to increasing prevalence of chronic diseases such as cancer, autoimmune disease, hepatitis, and others of infections. For instance, according to an article published in the NCBI in December 2020, the estimated number of people with multiple sclerosis worldwide has increased to 2.8 million in 2020. When compared to 2013, the estimate is 30% higher than in 2013. The 2020 global prevalence was 35.9 per 100,000 people.
Among type, consumables segment is expected to hold a dominant position over the forecast period, owing to increasing availability of PEGylated consumables such as reagents and kits. For instance, ThermoFisher Scientific Inc., a multinational biotechnology company, offers a broad range of PEG reagents in three types - Crosslinking Reagents, Biotin Labeling Reagents, and Pegylation Reagents.
On the basis of protein, colony-stimulating factor segment is expected to hold a dominant position over the forecast period, owing to increasing research and development activities to evaluate the use of Colony Stimulating Factors (CSFs) in various conditions by the key players in the market. For instance, in March 2022, Partner Therapeutics, Inc., a commercial biotech company, announced publication of results from investigator-sponsored pre-clinical research that evaluated the use of recombinant murine GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) in improving cognitive ability and brain pathology in an aged mouse model of Down syndrome and in aged normal mice. According to the results of the study, the immune system stimulating cytokine GM-CSF improved learning/memory and interneuron and astrocyte brain pathology in Dp16 down syndrome mice and improved learning/memory in wild-type mice.
Competitive Landscape:
Key players operating in the global PEGylated proteins market include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5354
Market Segmentation:
- Global PEGylated Proteins Market, By Type:
- Consumables
- Services
- Global PEGylated Proteins Market, By Protein:
- Colony-stimulating factor
- Interferons
- Erythropoietin
- Recombinant factor VII
- Other
- Global PEGylated Proteins Market, By Application:
- Cancer
- Autoimmune Disease
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorder
- Others
- Global PEGylated Proteins Market, By End User:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Global PEGylated Proteins Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Single-Use Bioreactor Market, By Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), By Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins, and Other Molecule Types), By End User (Pharmaceutical and Biopharmaceutical Industries and Contract Research Organizations (CRO) Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
Antifreeze Proteins Market, by Product Type (Type I, Type III, Antifreeze Glycoproteins, and Others), by Form (Solid and Liquid), by Source (Fish, Recombinant (Bacteria, Fungi, Plant, and Animals)), by End User (Medical Industry, Food & Beverages Industry, Cosmetics Industry, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
